LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.62M | -2.05M | -786.20K | -856.70K | -281.20K |
| Total Depreciation and Amortization | 776.70K | 594.80K | 530.80K | 440.00K | 511.00K |
| Total Amortization of Deferred Charges | -- | -- | 4.30K | -- | -- |
| Total Other Non-Cash Items | 859.00K | 507.40K | -1.20M | 1.21M | 526.90K |
| Change in Net Operating Assets | 800.50K | -1.63M | 2.15M | -4.00M | 318.00K |
| Cash from Operations | 816.40K | -2.58M | 696.50K | -3.21M | 1.07M |
| Capital Expenditure | -293.30K | -179.30K | -254.60K | -616.40K | -318.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -1.79M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -664.00K | -432.30K | -1.02M | -519.10K | -393.90K |
| Cash from Investing | -957.30K | -611.60K | -3.07M | -1.14M | -711.90K |
| Total Debt Issued | 1.75M | 5.75M | 8.81M | 8.39M | 5.63M |
| Total Debt Repaid | -618.00K | -613.00K | -3.91M | -8.19M | -671.00K |
| Issuance of Common Stock | -- | -- | 41.00K | 2.28M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -732.00K | -540.00K | -1.54M | -1.01M | -667.00K |
| Cash from Financing | 285.40K | 3.35M | 2.44M | 1.06M | 3.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.50K | 159.60K | 71.00K | -3.28M | 3.46M |